Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D

16:39 EST 15 Jan 2020 | Xconomy

Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing. The Series B round was led by AnGes, a Japan-based biopharmaceutical company. New York-based Emendo did not respond to a request for comment. But on its website, it contends that CRISPR is […]

Original Article: Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D


More From BioPortfolio on "Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D"

Quick Search

Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...